Natera Inc. ( (NTRA) ) has released its Q1 earnings. Here is a breakdown of the information Natera Inc. presented to its investors.
Natera Inc. is a global leader in cell-free DNA and genetic testing, focusing on oncology, women’s health, and organ health, with a commitment to making personalized genetic testing a standard of care.
In its first quarter of 2025, Natera reported significant financial growth, with total revenues reaching $501.8 million, marking a 36.5% increase from the previous year. The company also achieved a gross margin of 63.1%, reflecting improvements in cost management and revenue collection.
Key highlights from the quarter include a 16.2% increase in processed tests, totaling approximately 855,100, and a notable 46.1% rise in oncology tests performed. Despite these achievements, Natera reported a net loss of $66.9 million, slightly improved from the previous year’s loss. The company also maintained a strong cash position with $991.6 million in cash and equivalents.
Looking ahead, Natera anticipates continued revenue growth, projecting total revenues between $1.94 billion and $2.02 billion for 2025. The company remains focused on expanding its product offerings and improving operational efficiencies to enhance its financial performance.